Protocol Ledger

NCT04603040 · Phase II · TERMINATED

A Study to Evaluate the Efficacy and Safety of Toripalimab Injection in the Treatment of Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy and

Interventional Phase II clinical trial protocol NCT04603040 sponsored by Shanghai Junshi Bioscience Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-09-28 Enrollment: 17 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04603040
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)17 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04603040
Protocol FieldVerified Registry Value
NCT IdentifierNCT04603040
Consolidated Lead SponsorShanghai Junshi Bioscience Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment17 participants (ACTUAL)
Registered Start Date2020-09-28
WhyStopped ClassificationUnspecified

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04603040
Hospital Research SiteLocationSite Profile
Sun Yat-sen University Cancer CenterGuangzhou, ChinaOpen Hospital Dossier ->
Affiliated Hospital of Hebei UniversityBaoding, ChinaOpen Hospital Dossier ->
Sichuan Cancer HospitalChengdu, ChinaOpen Hospital Dossier ->
Guangdong Provincial People's HospitalGuangzhou, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI